EHA 2023 | Gilteritinib maintenance after allogeneic transplantation in FLT3-mutated AML
Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, comments on the results of a real-world study evaluating the safety and efficacy of gilteritinib maintenance after allogeneic stem cell transplantation (alloSCT) in patients with FLT3-mutated acute myeloid leukemia (AML). The study reported a manageable toxicity profile, with a prolonged CR on gilteritinib maintenance and conversion from measurable residual disease (MRD) positivity to MRD negativity. In addition, some patients experienced clonal evolution. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Abbvie: Consultancy, Honoraria, Other: Travel Expenses; Astellas: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Other: Travel Expenses; Pfizer: Consultancy
